Form 8-K - Current report:
SEC Accession No. 0000950170-23-020569
Filing Date
2023-05-10
Accepted
2023-05-10 16:21:46
Documents
14
Period of Report
2023-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tpst-20230510.htm   iXBRL 8-K 57764
2 EX-99.1 tpst-ex99_1.htm EX-99 222662
3 GRAPHIC img73128808_0.jpg GRAPHIC 34814
  Complete submission text file 0000950170-23-020569.txt   454281

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tpst-20230510_lab.xml EX-101.LAB 12806
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tpst-20230510_pre.xml EX-101.PRE 9455
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tpst-20230510.xsd EX-101.SCH 2472
8 EXTRACTED XBRL INSTANCE DOCUMENT tpst-20230510_htm.xml XML 4535
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 23906796
SIC: 2834 Pharmaceutical Preparations